Canopy Growth (CGC) Competitors

Travere Therapeutics (NASDAQ:TVTX) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Do insiders and institutionals hold more shares of TVTX or CGC?

3.3% of Canopy Growth shares are owned by institutional investors. 3.8% of Travere Therapeutics shares are owned by insiders. Comparatively, 1.3% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has more risk and volatility, TVTX or CGC?

Travere Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.

Does the MarketBeat Community favor TVTX or CGC?

Travere Therapeutics received 57 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 57.04% of users gave Travere Therapeutics an outperform vote while only 19.42% of users gave Canopy Growth an outperform vote.

Company	Underperform	Outperform
Travere Therapeutics	Outperform Votes 77 57.04%	Underperform Votes 58 42.96%
Canopy Growth	Outperform Votes 20 19.42%	Underperform Votes 83 80.58%

Does the media prefer TVTX or CGC?

In the previous week, Travere Therapeutics and Travere Therapeutics both had 8 articles in the media. Travere Therapeutics' average media sentiment score of 0.74 beat Canopy Growth's score of 0.16 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Canopy Growth	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate TVTX or CGC?

Travere Therapeutics currently has a consensus price target of $22.62, suggesting a potential upside of 27.63%. Canopy Growth has a consensus price target of $3.50, suggesting a potential downside of 6.17%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Travere Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Which has stronger valuation and earnings, TVTX or CGC?

Travere Therapeutics has higher earnings, but lower revenue than Canopy Growth. Travere Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$203.45M	6.80	-$111.40M	-$4.55	-3.89
Canopy Growth	$220.27M	1.59	-$487.23M	-$4.93	-0.76

Is TVTX or CGC more profitable?

Travere Therapeutics has a net margin of -172.75% compared to Canopy Growth's net margin of -186.17%. Canopy Growth's return on equity of -74.29% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-172.75%	-537.74%	-55.65%
Canopy Growth	-186.17%	-74.29%	-29.94%

Summary

Travere Therapeutics beats Canopy Growth on 11 of the 17 factors compared between the two stocks.